|
Apr 24
|
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
|
|
Aug 1
|
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
|
|
Jul 29
|
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
|